Funding and Grants

Current Funding Opportunities

MCW Cancer Center Pilot Funding Program►OPEN NOW MCW Cancer Center Pilot Funding Program, Spring 2017 RFA

 

 

 

 

MCW Cancer Center Pilot Funding Award Cycles

 

Spring 2017

Fall 2018

RFA Released

5/19/17

11/15/2017

LOI Due

6/2/2017

12/1/2017

Application Due

7/17/2017

1/15/2018

Review Committees

8/21 - 9/1/2017

2/15 – 2/26/2018

Funding Decision

First Thursday of October

First Thursday of April

Earliest Start Date

1/1/2018

6/1/2018

 

National Cancer Institute (NCI)

Open AllClose All
  Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01) (Deadline: 6/28/17)

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Applications due June 28, 2017

  Research Answers to NCI's Provocative Questions (R01) (Deadline: 6/28/17)

Research Answers to NCI's Provocative Questions (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances.

The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Applications due June 28, 2017

  Research Answers to NCI's Provocative Questions (R21) (Deadline: 6/28/17)

Research Answers to NCI's Provocative Questions (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.

Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances.

The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

Applications due June 28, 2017

  Revision Applications to National Cancer Institute (NCI)-Supported P01 Awards to Include Research on the NCI's Provocative Questions (P01) (Deadline: 6/28/17)

Revision Applications to National Cancer Institute (NCI)-Supported P01 Awards to Include Research on the NCI's Provocative Questions (P01)

This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NCI P01 Program Projects. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P01 award.

Applications due June 28, 2017

  Revision Applications to National Cancer Institute (NCI)-Supported P50 Awards to Include Research on the NCI's Provocative Questions (P50) (Deadline: 6/28/17)

Revision Applications to National Cancer Institute (NCI)-Supported P50 Awards to Include Research on the NCI's Provocative Questions (P50)

This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NCI P50 Specialized Centers. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published in RFA-CA-17-017 and RFA-CA-17-018 that are intended for new R01 and R21 applications, respectively. This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to a new research project expanding the scope, yet integrated into the overall theme, of the entire parent P50 award.

Applications due June 28, 2017

  Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01) (Deadline: 6/28/17)

Revision Applications to NCI-supported R01 Awards to Include Research on the NCI's Provocative Questions (R01)

This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent R01 award.

Applications due June 28, 2017

  Revision Applications to National Cancer Institute (NCI)-Supported U01 Awards to Include Research on the NCI's Provocative Questions (U01) (Deadline: 6/28/17)

Revision Applications to National Cancer Institute (NCI)-Supported U01 Awards to Include Research on the NCI's Provocative Questions (U01)

This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI U01 research project awards. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-17-017 (R01) and RFA-CA-17-018 (R21). This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01 award.

Applications due June 28, 2017

  6/29/17 Pre-application Webinar for PAR-16-166 “Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)”

Notice of Pre-application Webinar for PAR-16-166 “Integrating Biospecimen Science Approaches into Clinical Assay Development (U01)”

The National Cancer Institute (NCI) will hold a public pre-application webinar on Thursday, June 29 at noon-1 p.m. (EST) for the Funding Opportunity Announcement (FOA) PAR-16-166 “Integrating Biospecimen Science approaches into Clinical Assay Development (U01)”.

NCI staff members involved in this FOA will provide orientation and technical assistance to potential applicants by explaining the goals and objectives of the research program and answering questions from attendees about the U01 Research Projects.

Webinar on Thursday, June 29 at 11 a.m.-noon (CST)

  LIMITED! Pediatric Early Phase Clinical Trials Network (UM1) (Deadline: 6/30/17 for Letter of Intent)

Pediatric Early Phase Clinical Trials Network (UM1)

The purpose of this Funding Opportunity Announcement (FOA) is to enhance NCI’s program for conducting early phase clinical trials in children with cancer, currently supported as the Children's Oncology Group (COG) Phase 1 & Pilot Consortium. The overall goal is to ensure that high priority novel agents can be tested in pediatric patients in a timely manner. Towards this end, the clinical research activities now supported through the COG Phase 1 & Pilot Consortium will be continued (and enhanced) by the Pediatric Early Phase Clinical Trials Network (PEP-CTN).

*Limited Submission
Because this is a limited submission opportunity, nominees will be picked by a review panel of adult and pediatric cancer experts.

By noon, Friday, June 30:

  • Send your Letter of Intent (2-Page Maximum) and Biosketch to nmdavis@mcw.edu
  • Applicants will be notified by July 14
  • Deadline for Application to NCI: August 16, 2017
  Metabolic Reprogramming to Improve Immunotherapy (R01) (Deadline: 7/5/17)

Metabolic Reprogramming to Improve Immunotherapy (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage R01 grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.

Applications due July 5, 2017

  Cooperative Agreement to Develop Targeted Agents for Use With Systemic Agents Plus Radiotherapy (U01) (Deadline: 7/14/17)

Cooperative Agreement to Develop Targeted Agents for Use With Systemic Agents Plus Radiotherapy (U01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

Applications due July 14, 2017

  Exploratory Grants in Cancer Epidemiology and Genomics Research (R21) (Deadline: 7/16/17)

Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)

This funding opportunity announcement (FOA) invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors.

Applications due July 16, 2017

  Metabolic Reprogramming to Improve Immunotherapy (R21) (Deadline: 7/16/17)

Metabolic Reprogramming to Improve Immunotherapy (R21)

The overall goal of this funding opportunity announcement (FOA) is to encourage R21 exploratory/developmental grant applications to (a) generate a mechanistic understanding of the metabolic processes that support robust anti-tumor immune responses in vivo, (b) determine how the metabolic landscape of the tumor microenvironment affects immune effector functions, and (c) then use this information to manipulate (reprogram) the metabolic pathways used by the tumor, the immune response, or both to improve cancer immunotherapy.

Applications due July 16, 2017

  Pilot and Feasibility Studies Evaluating the Role of RNA Modifications (the 'epitranscriptome') in Cancer Biology (R21) (Deadline: 7/16/17)

Pilot and Feasibility Studies Evaluating the Role of RNA Modifications (the 'epitranscriptome') in Cancer Biology (R21)

This Funding Opportunity Announcement (FOA) encourages basic research into the role of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer. Chemical modifications of RNA bases have been reported to regulate the fate and function of both coding and noncoding RNAs and are emerging as a critical element of post-transcriptional gene regulation. This FOA will utilize the Exploratory/Developmental (R21) mechanism which supports investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or biobehavioral research.

Applications due July 16, 2017

  HIV/AIDS and the Tumor Niche (R01) (Deadline: 8/5/17

HIV/AIDS and the Tumor Niche (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).

Applications due August 5, 2017

  Inter-organelle Communication in Cancer (R01) (Deadline: 8/16/17)

Inter-organelle Communication in Cancer (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.  

Applications due August 16, 2017

  Inter-organelle Communication in Cancer (R21) (Deadline: 8/16/17)

Inter-organelle Communication in Cancer (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.

Applications due August 16, 2017

  Cancer Prevention Fellowship Program (CPFP) (Deadline: 8/25/17)

Cancer Prevention Fellowship Program (CPFP)

The NCI Cancer Prevention Fellowship Program provides postdoctoral training opportunities in cancer prevention and control. Under the shared guidance of an individual NCI preceptor and the CPFP scientific staff, fellows will develop original research projects in cancer prevention and control. Collaboration with investigators throughout the NCI is encouraged. Research opportunities include, but are not limited to

  • biomarker development,
  • chemoprevention studies,
  • clinical cancer prevention research,
  • effectiveness and outcomes research,
  • epidemiology (clinical, environmental, genetic, molecular, nutritional),
  • ethics and evidence-based decision making (theoretical and practical studies),
  • health disparities and special populations,
  • laboratory-based research (chemoprevention, molecular biology and genetics, nutritional science),
  • screening and early detection,
  • social and behavioral research, and
  • statistical methodology (biometry and bioinformatics).

Preceptors who serve to guide and enrich each fellow's experience are selected from skilled investigators across all NCI divisions, participating FDA centers, or local academic institutions.

Applications due to NCI August 25, 2017

  US Tobacco Control Policies to Reduce Health Disparities (R01) (Deadline: 10/11/17)

US Tobacco Control Policies to Reduce Health Disparities (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

Application due October 11, 2017

  US Tobacco Control Policies to Reduce Health Disparities (R21) (Deadline: 10/11/17)

US Tobacco Control Policies to Reduce Health Disparities (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

Application due October 11, 2017

  KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research (Deadline: 10/27/17)

KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research

The KRAS Fellowship provides $100,000 in research funding over a two-year period. The grant term begins on July 1, 2017, and concludes on June 30, 2019. In addition to the research grant, Fellows are provided with $5,000 in travel support plus housing to visit FNLCR.

During the grant term, Fellows are given guest researcher status at FNLCR and are trained and granted access to onsite technology to support their funded research. They also receive support from the RAS Initiative team in planning experimental approaches for their funded project, mentorship from the RAS Initiative leadership and opportunities to participate in scientific lab meetings and workshops and to forge collaborations with other RAS researchers.

Fellows also attend the Pancreatic Cancer Action Network's Annual Scientific Meeting (scheduled for August 17-20, 2017, and dates to be determined in 2018 and 2019). This meeting brings together grant recipients and members of the organization’s Scientific and Medical Advisory Board for research feedback, knowledge exchange, mentorship and collaboration. Support for travel to the annual meeting is provided separate from the Fellowship grant.

Applications due October 27, 2017

National Institutes of Health (NIH)

Open AllClose All
  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

  Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01) (Deadline: 7/5/17)

Research to Advance the Understanding and Management of the Multiple Organ Dysfunction Syndrome in Children (R01)

The purpose of this funding opportunity announcement (FOA) is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more basic, exploratory and longitudinal research.

Possible topics of study include, but are not limited, to the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study designs ranging from basic science and animal models through prospective randomized controlled trials. It is hoped that as a result of research supported through this funding opportunity, outcomes will improve both in terms of the prevention and treatment of MODS in children.

Applications due July 5, 2017

  The Role of Mobile Genetic Elements in Cancer (R01) (Deadline: 7/5/17)

The Role of Mobile Genetic Elements in Cancer (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer.

For example, although long interspersed element-1 (LINE-1 or L1) retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood.

In an effort to address this knowledge gap, this FOA invites research applications that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy.

Applications due July 5, 2017

  The Role of Mobile Genetic Elements in Cancer (R21) (Deadline: 7/16/17)

The Role of Mobile Genetic Elements in Cancer (R21)

The overall goal of this funding opportunity announcement (FOA) is to encourage applications to investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer.

For example, although long interspersed element-1 (LINE-1 or L1) retroelements are active in many cancers whether somatic L1 insertions lead to cancer cell heterogeneity and/or adaptive phenotypes that confer growth or survival advantages during cancer evolution or response to therapy is not clear. Similarly, how human endogenous viruses (HERVs) affect cancer processes is also not well understood.

In an effort to address this knowledge gap, this FOA invites research proposals that specifically investigate mechanisms regulating the expression and activity of mobile genetic elements in the context of cell transformation and assess the impact of their activity on tumor heterogeneity, cancer evolution, and response to therapy. 

Applications due July 16, 2017

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  Stand Up To Cancer - Lustgarten Foundation Pancreatic Cancer Interception Dream Team (Deadline: 6/26/17)

Stand Up To Cancer - Lustgarten Foundation Pancreatic Cancer Interception Dream Team

Submissions of ideas will be invited for a translational cancer research project that addresses critical problems in pancreatic cancer and positively impacts patients in the near future, with the goal of advancing innovative approaches to prevent or intercept the disease-causing process, and making data available in a format amenable to open access analytics. Prioritized areas of interest include both applied and fundamental research including: The discovery and implementation of innovative methods that effectively detects pancreatic cancer at an early and surgically curable stage; new tools for monitoring disease progression and therapeutic response, which could potentially serve as surrogate endpoints for clinical trials and regulatory approval; investigation of novel chemoprevention or immune prevention approaches; the development of risk prognostication methods for pre-invasive pancreatic neoplasms and other conditions that elucidates the molecular details underlying that increased risk; the understanding of immune suppression and inflammation mechanisms that promote pancreatic cancer and the design of methods to circumvent this; and more generally research targeted at generating sufficient knowledge to justify a clinical intervention to test novel hypotheses related to early detection and treatment of pancreatic cancer.

This proposed project is expected to benefit patients through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators. Priority will be given to applications that are characterized by a diversity of team members, including those from fields outside the traditional realms of biomedical research (e.g. physics, mathematics, engineering, health policy, and communications). Specific aims of the project may include basic research, translational studies, and population studies but the overall proposal must have a strong clinical research component. Proposals for this Dream Team research project must present plans indicating how the work will be translated into clinical application. The concepts will be evaluated on innovation, feasibility, opportunities for success and further development, including improved long-term outcomes for patients.

Applications due June 26, 2017

  Educational Grants (Bayer AG; Bayer USA Foundation) (Deadlines: 8/8/17 for Oncology; 10/1/17 for Generic Education)

Educational Grants (Bayer AG; Bayer USA Foundation)

The goal of the contributions and educational grants initiatives is to promote the general prevention and treatment of disease and illness. Bayer strategically focuses its funding in support of research, education and patient support. As a commitment to improving patient care and providing valuable information to the medical and broader healthcare community, Bayer HealthCare will accept the following grant requests:

  1. Healthcare professional education
  2. Patient advocacy and Consumer education programs (e.g., disease-state education and awareness, screenings, camps, etc.)

Areas of Support:

  • Dermatology
  • Radiology
  • Hematology-Hemophilia
  • General Medicine (Pulmonology/Cardiology/Infectious Disease/Non-Cystic Fibrosis Bronchiectasis)
  • Neurology
  • Women's Health

Oncology:

  • Advanced Prostate Cancer
  • Colorectal Cancer
  • Gastrointestinal Stromal Tumor
  • Hepatocellular Carcinoma
  • Thyroid Cancer

Applications due August 8, 2017 (Oncology); October 1, 2017 (Generic Education)

  St Baldrick’s Foundation (SBF) (Deadline: 8/31/17)

St Baldrick’s Foundation (SBF)

These grants are not for a specific research project, but rather for resources to allow more research to be done. They support institutions with the potential for more participation in childhood cancer clinical trials, but which currently lack necessary resources (primarily support for Clinical Research Associates). Infrastructure grants are designed to provide an infusion of funds to enable an institution to acquire the personnel (i.e., a clinical research associate) or resources it needs to reach its potential in broader clinical trial participation. The applicant should indicate how ongoing personnel costs will be funded in future years.

Applications due August 31, 2017

  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

Other

Open AllClose All
  Developing Biomarkers for Trastuzumab-induced Cardiotoxicity (R30) (Deadline: 7/10/17)

Developing Biomarkers for Trastuzumab-induced Cardiotoxicity (R30)

Underlining problems related to cardiac dysfunction caused by antibody-based HER2 targeted therapies are very important issues related to women’s health. Innovative methods to detect potential cause(s) of cardiotoxicity are urgently needed to improve the quality of life for women with HER2-positive breast cancer. Recent data obtained from several large clinical trials have demonstrated that cardiomyopathy induced by trastuzumab is irreversible in many patients. Therefore, it is important to develop sensitive and specific testing methods and biomarkers that could detect potential cardiotoxicity induced by trastuzumab therapy to provide important information to support effective post-marketing surveillance program.

Application due July 10, 2017

  AACR-Bayer Innovation and Discovery Grants (Deadline 7/13/17)

AACR-Bayer Innovation and Discovery Grants

This grants partnership will promote the key tenets of the Bayer Grants4Targets™ Initiative, providing new treatment options for cancers with high unmet medical need, encouraging innovation and translation of ideas from basic research into novel drugs, and fostering collaborations between excellent academic groups and the pharmaceutical industry. This program offers one-year grants of $25,000 to meritorious projects that examine important, and druggable*, novel targets and biomarkers.

Applications due July 13, 2017

  Breast Cancer Alliance (BCA) (Deadline: 7/22/17)

Breast Cancer Alliance (BCA)

The mission of the Breast Cancer Alliance (BCA) is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, the BCA invests in innovative research, breast surgery fellowships, regional education, dignified support and screening for the uninsured and underserved.

The BCA offers the Young Investigator Grant to encourage a commitment to breast cancer research. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support.

Applications due July 22, 2017

  Brian D. Novis Senior Research Award (Deadline: 8/1/17)

Brian D. Novis Senior Research Award

These awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance) as well as immunoglobulin derived amyloidosis. These awards are targeted to established investigators with a track record in myeloma or related disorders, and are designed for projects which represent a different focus, direction, or area of research from those in which they are currently funded.

In most cases, these awards will be for pilot projects to obtain sufficient funding for larger applications from NIH or similar larger funding agencies.

Applications due August 1, 2017

  Radiation Science and Technology Award (Deadline: 8/1/17)

Radiation Science and Technology Award

Established in 1967, this award recognizes outstanding creative applications of radiation sciences and engineering principles. Qualification is based on meritorious scientific and engineering achievement that has important implications for radiation science and technology. The work may have been performed at any time in the past, but the findings must have been reported in peer reviewed scientific journals. In addition, the feasibility of industrial application(s) must have been established although the work need not be in widespread use at the time of the award. The nominee need not be an ANS member. Any ANS member can nominate a worthy candidate.

Nominations due August 1, 2017

  Gilead Sciences Research Scholars Program in Hematology/Oncology (Deadline 9/8/17)

Gilead Sciences Research Scholars Program in Hematology/Oncology

The mission of the program is to support innovative scientific research that will advance knowledge in the field of hematology/oncology, with a focus on hematologic malignancies, and provide support for research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding in hematology/oncology.

The program is designed to support innovative translational research projects in hematology/oncology, with a focus on hematologic malignancies, that can be either based around a clinical trial with strong correlative science or laboratory investigation.

Applications due September 8, 2017

  Prostate Cancer Research Program (PCRP)- Physician Research Award (Deadline: 8/10/17)

Prostate Cancer Research Program (PCRP)- Physician Research Award

The Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research.

Applications due August 10, 2017

  Stand Up To Cancer (SU2C) Dream Team Translational Research Grant (Deadline: LOI by 9/5/17; Invited Full Proposal by 1/16/18)

Stand Up To Cancer (SU2C) Dream Team Translational Research Grant

The Stand Up To Cancer Dream Team Translational Research Grant will fund a translational cancer research project that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.

The ideas may focus on particular organ sites, patient populations (such as pediatrics) or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.

LOI due September 5, 2017

Invited full proposals due January 16, 2018

  Clinical Investigator Career Development Grant (Deadline: 9/6/17)

Clinical Investigator Career Development Grant

The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission and publication. As such, a Career Development Plan is required as part of the Grant Application. The proposed research plan should also develop the necessary knowledge and clinical research skills relevant to the investigator's career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clini cal research studies in lymphoma.

**All projects must be focused on hypothesis-driven clinical research in lymphoma. The project should be developed by the Applicant and should include at least the framework of a research protocol**

Applications due September 6, 2017

  CONquer canCER Now Award (Deadlines: LOI by 9/7/17; Full Proposal by 12/7/17)

CONquer canCER Now Award

By specifically targeting promising early-career scientists and providing critically needed "seed" money for innovative projects, Concern Foundation supports development of the next generation of cancer researchers and thus promotes progress in understanding cancer biology and improved approaches to cancer.

**Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology**

Concern will not fund clinical trials, cancer epidemiology, or behavioral studies.

LOI due September 7, 2017

Full Proposal due December 7, 2017

  Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA) (Deadline: 9/7/17)

Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA)

The mission of the FY17 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.

Applications due September 7, 2017

  Prostate Cancer Research Program (PCRP)- Pathology Resource Network Award (Deadline: 9/7/17)

Prostate Cancer Research Program (PCRP)- Pathology Resource Network Award

The FY17 PCRP PCPRN Award is intended to provide infrastructure support for the development and maintenance of a prostate cancer biorepository through a collaborative network across multiple institutions that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human prostate cancer biospecimens. A major focus of the Network must be placed on the acquisition and distribution of specimens in limited supply, such as:

  • Castration-resistant disease, metastatic disease, primary untreated "de novo" metastatic disease as defined by STAMPEDE or high-risk disease defined by CHAARTED, tumors of the aggressive variant phenotype
  • Disproportionately affected populations, defined by ethnicity or health service access (safety net, rural, settings)
  • Active surveillance populations
  • Longitudinal/sequential specimens

The Network must also collect, store, and manage data derived from the distributed biospecimens, including images of the hematoxylin and eosin (H&E)-stained samples.

Applications due September 7, 2017

  Prostate Cancer Research Program (PCRP)- Health Disparity Research Award (Deadline: 9/28/17)

Prostate Cancer Research Program (PCRP)- Health Disparity Research Award

The Health Disparity Research Award supports new ideas based on innovative concepts or methodologies for health disparity research with the potential to make an important contribution toward eliminating death from prostate cancer and enhancing the well-being of men impacted by the disease. Studies proposed for this award mechanism are expected to improve the understanding of and/or address factors that contribute to differences in the disease experience across populations, ultimately contributing to eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship.

Applicants for this award must explicitly state how the proposed research is related to an area of prostate cancer health disparity. The PCRP is interested in research that addresses all different aspects that contribute to health disparity in prostate cancer, including social, cultural, and/or biological contributors. Because of the emphasis on innovation, the inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required.

Any preliminary, unpublished data provided should be from the Principal Investigator (PI) or a member(s) of the research team.

Applications due September 28, 2017

  Administrative Supplements for Research on Dietary Supplements (Admin Supp) (Deadline: 10/15/17)

Administrative Supplements for Research on Dietary Supplements (Admin Supp)

This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention.

Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention.

Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease.

This FOA will not support new clinical trials.

Applications due October 15, 2017

  Desmoid Tumor Research Foundation (Deadline: 1/12/18)

Desmoid Tumor Research Foundation

The Desmoid Tumor Research Foundation, Inc. (“DTRF”) funds research that will advance the current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure. DTRF is the only foundation in the world dedicated to facilitating and funding research for a cure for desmoid tumors.

We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research. Research proposals with additional sources of funding support are particularly desirable. Researchers must be willing to collaborate with other scientists and institutions with similar interests. Grantees must agree to participate as reviewers in DTRF’s future grant review cycle, as well as to exert best efforts to attend the annual fall International DTRF Desmoid Tumor Research Workshop

Applications due January 12, 2018

  Fanconi Anemia Research Fund (Deadline: 2/2/18)

Fanconi Anemia Research Fund

The Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control or cure Fanconi anemia. It has a particular interest in funding interdisciplinary, translational research efforts that effectively address one or more of the following priorities:

  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat and cure these disorders.
  • To define the pathogenesis of cancers that affect persons with Fanconi anemia, and to develop strategies for early detection, prevention, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to develop and maintain a high quality of life.
  • To support the creation of shared resources, databases and technologies for the international Fanconi anemia research community.

Applications due February 02, 2018

  Adenoid Cystic Carcinoma Research Foundation (Deadline: Continuous)

Adenoid Cystic Carcinoma Research Foundation

Adenoid Cystic Carcinoma (ACC) is a rare malignancy of secretory glands, typically originating in the salivary glands though it does appear in other primary sites, including the palate, nasopharynx, tongue base, larynx, trachea, lacrimal gland, breast and vulva. There are approximately 1,200 new cases of ACC diagnosed each year in the United States, about 60% of which involve women. This cancer has a slow, and sometimes relentless, progression characterized by frequent recurrences and metastases to sites such as the lungs, liver and bones.

Deadline continuous

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)] (Deadline Continuous)

UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]

The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.

  • Research plan
    • Cancer prevention and control (including tobacco control)
    • Basic, applied and clinical cancer research Epidemiology,
    • Cancer registration, public education and behavioral sciences
  • Clinical training
    • Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
    • Clinical trials
    • Detection and diagnosis Prevention-oriented projects are especially encouraged

Deadline Continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

FOLLOW:

 

Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
(414) 955-8296
Directions & Maps
© 2017

 

 

Page Updated 06/22/2017
Top